Skip to main content
SpringerLink
Log in

Medical Management of Infantile Hemangiomas: An Update

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Infantile hemangioma (IH) is the most common benign vascular tumor of infancy, affecting about 5% of infants. It has a characteristic growth pattern of early rapid proliferation followed by progressive involution. Although most IH evolve favorably, complications are observed in 10–15% of cases, justifying treatment. For over 10 years now, propranolol has become the first-line therapy for complicated IH, revolutionizing their management and their prognosis. In this article, we review the clinical features, associations, complications/sequelae and therapeutic approaches for IH, focusing on current medical therapy. Indications for treatment and various treatment options, including propranolol and other oral β-blockers, topical timolol, and corticosteroids are presented. Current controversies regarding oral propranolol such as pre-treatment screening, in- vs out-patient initiation of treatment, early and potential long-term side effects and recommended monitoring are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170(4):907–13. https://doi.org/10.1111/bjd.12804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85–94. https://doi.org/10.1016/s0140-6736(16)00645-0.

    Article  PubMed  Google Scholar 

  3. Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019. https://doi.org/10.1542/peds.2018-3475.

    Article  PubMed  Google Scholar 

  4. Rotter A, de Oliveira ZNP. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. J Dtsch Dermatol Ges. 2017;15(12):1185–90. https://doi.org/10.1111/ddg.13365.

    Article  PubMed  Google Scholar 

  5. Ji Y, Chen S, Xu C, Li L, Xiang B. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2015;172(1):24–32. https://doi.org/10.1111/bjd.13388.

    Article  CAS  PubMed  Google Scholar 

  6. Harter N, Mancini AJ. Diagnosis and management of infantile hemangiomas in the neonate. Pediatr Clin N Am. 2019;66(2):437–59. https://doi.org/10.1016/j.pcl.2018.12.011.

    Article  Google Scholar 

  7. Bauland CG, Lüning TH, Smit JM, Zeebregts CJ, Spauwen PHM. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg. 2011;127(4):1643–8. https://doi.org/10.1097/PRS.0b013e318208d2ac.

    Article  CAS  PubMed  Google Scholar 

  8. Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360–7. https://doi.org/10.1542/peds.2007-2767.

    Article  PubMed  Google Scholar 

  9. Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents’ photographs tell us. Pediatrics. 2012;130(2):e314–20. https://doi.org/10.1542/peds.2011-3683.

    Article  PubMed  Google Scholar 

  10. Baselga E, Roe E, Coulie J, Muñoz FZ, Boon LM, McCuaig C, et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatol. 2016;152(11):1239–43. https://doi.org/10.1001/jamadermatol.2016.2905.

    Article  PubMed  Google Scholar 

  11. Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg. 2012;130(3):619–24. https://doi.org/10.1097/PRS.0b013e31825dc129.

    Article  CAS  PubMed  Google Scholar 

  12. Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Diagnosis and management of infantile hemangioma: executive summary. Pediatrics. 2015;136(4):786–91. https://doi.org/10.1542/peds.2015-2482.

    Article  PubMed  Google Scholar 

  13. O’Brien KF, Shah SD, Pope E, Phillips RJ, Blei F, Baselga E, et al. Late growth of infantile hemangiomas in children > 3 years of age: a retrospective study. J Am Acad Dermatol. 2019;80(2):493–9. https://doi.org/10.1016/j.jaad.2018.07.061.

    Article  PubMed  Google Scholar 

  14. Drolet B, Garzon M. SACRAL syndrome. Dermatology. 2007;215(4):360. https://doi.org/10.1159/000107633 (Author reply-1).

    Article  PubMed  Google Scholar 

  15. Girard C, Bigorre M, Guillot B, Bessis D. PELVIS syndrome. Arch Dermatol. 2006;142(7):884–8. https://doi.org/10.1001/archderm.142.7.884.

    Article  PubMed  Google Scholar 

  16. Lee TO, Messner A. Subglottic hemangioma. Otolaryngol Clin N Am. 2008;41(5):903–11. https://doi.org/10.1016/j.otc.2008.04.009.

    Article  Google Scholar 

  17. Ji Y, Chen S, Yang K, Xiang B, Jiang X, Xu X, et al. Screening for infantile hepatic hemangioma in patients with cutaneous infantile hemangioma: a multicenter prospective study. J Am Acad Dermatol. 2020;84(5):1378–84. https://doi.org/10.1016/j.jaad.2020.11.062.

    Article  PubMed  Google Scholar 

  18. Hermans DJ, Boezeman JB, Van de Kerkhof PC, Rieu PN, Van der Vleuten CJ. Differences between ulcerated and non-ulcerated hemangiomas, a retrospective study of 465 cases. Eur J Dermatol. 2009;19(2):152–6. https://doi.org/10.1684/ejd.2008.0576.

    Article  PubMed  Google Scholar 

  19. Fernández Faith E, Shah S, Witman PM, Harfmann K, Bradley F, Blei F, et al. Clinical features, prognostic factors, and treatment interventions for ulceration in patients with infantile hemangioma. JAMA Dermatol. 2021. https://doi.org/10.1001/jamadermatol.2021.0469.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Dubois J, Garel L. Imaging and therapeutic approach of hemangiomas and vascular malformations in the pediatric age group. Pediatr Radiol. 1999;29(12):879–93. https://doi.org/10.1007/s002470050718.

    Article  CAS  PubMed  Google Scholar 

  21. Iacobas I, Phung TL, Adams DM, Trenor CC 3rd, Blei F, Fishman DS, et al. Guidance document for hepatic hemangioma (infantile and congenital) evaluation and monitoring. J Pediatr. 2018;203:294-300.e2. https://doi.org/10.1016/j.jpeds.2018.08.012.

    Article  PubMed  Google Scholar 

  22. Mahon C, McHugh K, Alband N, Rampling D, Sebire N, Williamson E, et al. Routine liver ultrasound screening does not alter clinical management in a cohort study of multiple cutaneous infantile haemangioma. Br J Dermatol. 2021;184(2):340–1. https://doi.org/10.1111/bjd.19472.

    Article  CAS  PubMed  Google Scholar 

  23. Solman L, Glover M, Beattie PE, Buckley H, Clark S, Gach JE, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. Br J Dermatol. 2018;179(3):582–9. https://doi.org/10.1111/bjd.16779.

    Article  CAS  PubMed  Google Scholar 

  24. Léauté-Labrèze C, Baselga Torres E, Weibel L, Boon LM, El Hachem M, van der Vleuten C, et al. The infantile hemangioma referral score: a validated tool for physicians. Pediatrics. 2020. https://doi.org/10.1542/peds.2019-1628.

    Article  PubMed  Google Scholar 

  25. Léauté-Labrèze C, de la Roque ED, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–51. https://doi.org/10.1056/NEJMc0708819.

    Article  PubMed  Google Scholar 

  26. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–46. https://doi.org/10.1056/NEJMoa1404710.

    Article  CAS  PubMed  Google Scholar 

  27. Léauté-Labrèze C, de la Roque ED, Nacka F, Abouelfath A, Grenier N, Rebola M, et al. Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age. Br J Dermatol. 2013;169(1):181–3. https://doi.org/10.1111/bjd.12217.

    Article  PubMed  Google Scholar 

  28. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128(2):e259–66. https://doi.org/10.1542/peds.2010-0029.

    Article  PubMed  Google Scholar 

  29. Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol. 2013;30(2):182–91. https://doi.org/10.1111/pde.12089.

    Article  PubMed  Google Scholar 

  30. Ahogo CK, Ezzedine K, Prey S, Colona V, Diallo A, Boralevi F, et al. Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. Br J Dermatol. 2013;169(6):1252–6. https://doi.org/10.1111/bjd.12432.

    Article  CAS  PubMed  Google Scholar 

  31. Kim KH, Choi TH, Choi Y, Park YW, Hong KY, Kim DY, et al. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. JAMA Dermatol. 2017;153(6):529–36. https://doi.org/10.1001/jamadermatol.2017.0250.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kridin K, Pam N, Bergman R, Khamaysi Z. Oral propranolol administration is effective for infantile hemangioma in late infancy: a retrospective cohort study. Dermatol Ther. 2020;33(3): e13331. https://doi.org/10.1111/dth.13331.

    Article  CAS  PubMed  Google Scholar 

  33. Wedgeworth E, Glover M, Irvine AD, Neri I, Baselga E, Clayton TH, et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European propranolol in the treatment of complicated haemangiomas (PITCH) taskforce survey. Br J Dermatol. 2016;174(3):594–601. https://doi.org/10.1111/bjd.14233.

    Article  CAS  PubMed  Google Scholar 

  34. Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128–40. https://doi.org/10.1542/peds.2012-1691.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Olsen GM, Hansen LM, Stefanko NS, Mathes E, Puttgen KB, Tollefson MM, et al. Evaluating the safety of oral propranolol therapy in patients with PHACE syndrome. JAMA Dermatol. 2020;156(2):186–90. https://doi.org/10.1001/jamadermatol.2019.3839.

    Article  PubMed  Google Scholar 

  36. Püttgen KB, Hansen LM, Lauren C, Stefanko N, Mathes E, Olsen GM, et al. Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.013.

    Article  PubMed  Google Scholar 

  37. Bassi A, Azzarelli A, Vaccaro A, Mazzatenta C. At-home dose escalation of propranolol for infantile hemangiomas during the COVID-19 pandemic. Dermatol Ther. 2020;33(6): e13977. https://doi.org/10.1111/dth.13977.

    Article  CAS  PubMed  Google Scholar 

  38. Baselga E, Dembowska-Baginska B, Przewratil P, González-Enseñat MA, Wyrzykowski D, Torrelo A, et al. Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma. Pediatrics. 2018. https://doi.org/10.1542/peds.2017-3866.

    Article  PubMed  Google Scholar 

  39. Shah SD, Baselga E, McCuaig C, Pope E, Coulie J, Boon LM, et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics. 2016. https://doi.org/10.1542/peds.2015-1754.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Frongia G, Byeon JO, Mehrabi A, Günther P. Recurrence rate of infantile hemangioma after oral propranolol therapy. Eur J Pediatr. 2021;180(2):585–90. https://doi.org/10.1007/s00431-020-03872-5.

    Article  CAS  PubMed  Google Scholar 

  41. Tiemann L, Hein S. Infantile hemangioma: a review of current pharmacotherapy treatment and practice pearls. J Pediatr Pharmacol Ther. 2020;25(7):586–99. https://doi.org/10.5863/1551-6776-25.7.586.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Al-Rwebah H, Alkhodair R, Al-Khenaizan S. Propranolol-induced hyperkalemia in the management of infantile hemangioma. JAAD Case Rep. 2020;6(4):359–61. https://doi.org/10.1016/j.jdcr.2020.01.028.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Cavalli R, Buffon RB, de Souza M, Colli AM, Gelmetti C. Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding? Dermatology. 2012;224(2):106–9. https://doi.org/10.1159/000337553.

    Article  CAS  PubMed  Google Scholar 

  44. Belen B, Oguz A, Okur A, Dalgic B. A complication to be aware of: hyperkalaemia following propranolol therapy for an infant with intestinal haemangiomatozis. BMJ Case Rep. 2014. https://doi.org/10.1136/bcr-2014-203746.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Pavlakovic H, Kietz S, Lauerer P, Zutt M, Lakomek M. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics. 2010;126(6):e1589–93. https://doi.org/10.1542/peds.2010-0077.

    Article  PubMed  Google Scholar 

  46. Ji Y, Chen S, Wang Q, Xiang B, Xu Z, Zhong L, et al. Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. Sci Rep. 2018;8(1):4264. https://doi.org/10.1038/s41598-018-22787-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Bagazgoitia L, Torrelo A, Gutiérrez JC, Hernández-Martín A, Luna P, Gutiérrez M, et al. Propranolol for infantile hemangiomas. Pediatr Dermatol. 2011;28(2):108–14. https://doi.org/10.1111/j.1525-1470.2011.01345.x.

    Article  PubMed  Google Scholar 

  48. McGee P, Miller S, Black C, Hoey S. Propranolol for infantile haemangioma: a review of current dosing regime in a regional paediatric hospital. Ulster Med J. 2013;82(1):16–20.

    PubMed  PubMed Central  Google Scholar 

  49. Bernabeu-Wittel J, Narváez-Moreno B, de la Torre-García JM, Fernández-Pineda I, Domínguez-Cruz JJ, Coserría-Sánchez F, et al. Oral nadolol for children with infantile hemangiomas and sleep disturbances with oral propranolol. Pediatr Dermatol. 2015;32(6):853–7. https://doi.org/10.1111/pde.12686.

    Article  PubMed  Google Scholar 

  50. Menezes MD, McCarter R, Greene EA, Bauman NM. Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. Ann Otol Rhinol Laryngol. 2011;120(10):686–95. https://doi.org/10.1177/000348941112001010.

    Article  PubMed  Google Scholar 

  51. Frost S, Saddi V, Teng A, Mallitt KA, Adams S, Williamson B, et al. Propranolol’s effects on the sleep of infants with hemangiomas: a prospective pilot study. Pediatr Dermatol. 2020. https://doi.org/10.1111/pde.14484.

    Article  PubMed  Google Scholar 

  52. Gonski K, Wargon O. Retrospective follow up of gross motor development in children using propranolol for treatment of infantile haemangioma at Sydney Children’s Hospital. Australas J Dermatol. 2014;55(3):209–11. https://doi.org/10.1111/ajd.12156.

    Article  PubMed  Google Scholar 

  53. Phillips RJ, Penington AJ, Bekhor PS, Crock CM. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. J Paediatr Child Health. 2012;48(10):902–6. https://doi.org/10.1111/j.1440-1754.2012.02521.x.

    Article  PubMed  Google Scholar 

  54. Mahon C, Heron G, Perkins D, Drage A, Wargon O. Oral propranolol for infantile haemangioma may be associated with transient gross motor delay. Br J Dermatol. 2018;178(6):1443–4. https://doi.org/10.1111/bjd.16334.

    Article  CAS  PubMed  Google Scholar 

  55. González-Llorente N, Del Olmo-Benito I, Muñoz-Ollero N, Descalzo MA, García-Doval I, Torrelo A. Study of cognitive function in children treated with propranolol for infantile hemangioma. Pediatr Dermatol. 2017;34(5):554–8. https://doi.org/10.1111/pde.13229.

    Article  PubMed  Google Scholar 

  56. Moyakine AV, Kerstjens JM, Spillekom-van Koulil S, van der Vleuten CJ. Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years. J Am Acad Dermatol. 2016;75(1):59-63.e1. https://doi.org/10.1016/j.jaad.2016.02.1218.

    Article  CAS  PubMed  Google Scholar 

  57. Moyakine AV, Hermans DJ, Fuijkschot J, van der Vleuten CJ. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development. J Am Acad Dermatol. 2015;73(2):341–2. https://doi.org/10.1016/j.jaad.2015.04.053.

    Article  PubMed  Google Scholar 

  58. Ábarzúa-Araya A, Navarrete-Dechent CP, Heusser F, Retamal J, Zegpi-Trueba MS. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol. 2014;70(6):1045–9. https://doi.org/10.1016/j.jaad.2014.01.905.

    Article  CAS  PubMed  Google Scholar 

  59. Koh SP, Leadbitter P, Smithers F, Tan ST. β-Blocker therapy for infantile hemangioma. Expert Rev Clin Pharmacol. 2020;13(8):899–915. https://doi.org/10.1080/17512433.2020.1788938.

    Article  CAS  PubMed  Google Scholar 

  60. Raphaël MF, de Graaf M, Breugem CC, Pasmans S, Breur J. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas. J Am Acad Dermatol. 2011;65(2):420–1. https://doi.org/10.1016/j.jaad.2010.11.056.

    Article  PubMed  Google Scholar 

  61. Ji Y, Wang Q, Chen S, Xiang B, Xu Z, Li Y, et al. Oral atenolol therapy for proliferating infantile hemangioma: a prospective study. Medicine (Baltimore). 2016;95(24): e3908. https://doi.org/10.1097/md.0000000000003908.

    Article  CAS  Google Scholar 

  62. de Graaf M, Raphael MF, Breugem CC, Knol MJ, Bruijnzeel-Koomen CA, Kon M, et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. J Plast Reconstr Aesthet Surg. 2013;66(12):1732–40. https://doi.org/10.1016/j.bjps.2013.07.035.

    Article  PubMed  Google Scholar 

  63. Bayart CB, Tamburro JE, Vidimos AT, Wang L, Golden AB. Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study. Pediatr Dermatol. 2017;34(4):413–21. https://doi.org/10.1111/pde.13177.

    Article  PubMed  Google Scholar 

  64. Tasani M, Glover M, Martinez AE, Shaw L. Atenolol treatment for infantile haemangioma. Br J Dermatol. 2017;176(5):1400–2. https://doi.org/10.1111/bjd.15317.

    Article  CAS  PubMed  Google Scholar 

  65. Alexopoulos A, Thanopoulou I, Dakoutrou M, Georgiadou E, Chrousos GP, Kakourou T. Atenolol treatment for severe infantile hemangiomas: a single-centre prospective study. J Eur Acad Dermatol Venereol. 2018;32(3):e117–9. https://doi.org/10.1111/jdv.14590.

    Article  CAS  PubMed  Google Scholar 

  66. Dakoutrou M, Alexopoulos A, Miligkos M, Georgiadou E, Kanaka-Gantenbein C, Kakourou T. Atenolol treatment for severe infantile hemangiomas: comparison with a propranolol group of our centre. J Eur Acad Dermatol Venereol. 2019;33(5):e199–200. https://doi.org/10.1111/jdv.15464.

    Article  CAS  PubMed  Google Scholar 

  67. Calderón-Castrat X, Velásquez F, Castro R, Ballona R. Oral atenolol for infantile hemangioma: case series of 46 infants. Actas Dermosifiliogr. 2020;111(1):59–62. https://doi.org/10.1016/j.ad.2019.03.015.

    Article  PubMed  Google Scholar 

  68. Zhao ZL, Liu C, Wang QZ, Wu HW, Zheng JW. Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients. Ann Transl Med. 2021;9(2):116. https://doi.org/10.21037/atm-20-5359.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Ji Y, Chen S, Yang K, Zhang X, Zhou J, Li L, et al. Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2021. https://doi.org/10.1001/jamaoto.2021.0454.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Laurens C, Abot A, Delarue A, Knauf C. Central effects of beta-blockers may be due to nitric oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier. Front Neurosci. 2019;13:33. https://doi.org/10.3389/fnins.2019.00033.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Pope E, Chakkittakandiyil A, Lara-Corrales I, Maki E, Weinstein M. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol. 2013;168(1):222–4. https://doi.org/10.1111/j.1365-2133.2012.11131.x.

    Article  CAS  PubMed  Google Scholar 

  72. McGillis E, Baumann T, LeRoy J. Death associated with nadolol for infantile hemangioma: a case for improving safety. Pediatrics. 2020. https://doi.org/10.1542/peds.2019-1035.

    Article  PubMed  Google Scholar 

  73. Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr. 1968;72(3):351–7. https://doi.org/10.1016/s0022-3476(68)80208-2.

    Article  CAS  PubMed  Google Scholar 

  74. Izadpanah A, Izadpanah A, Kanevsky J, Belzile E, Schwarz K. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg. 2013;131(3):601–13. https://doi.org/10.1097/PRS.0b013e31827c6fab.

    Article  CAS  PubMed  Google Scholar 

  75. Chinnadurai S, Fonnesbeck C, Snyder KM, Sathe NA, Morad A, Likis FE, et al. Pharmacologic interventions for infantile hemangioma: a meta-analysis. Pediatrics. 2016;137(2): e20153896. https://doi.org/10.1542/peds.2015-3896.

    Article  PubMed  Google Scholar 

  76. Aly MM, Hamza AF, Abdel Kader HM, Saafan HA, Ghazy MS, Ragab IA. Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. Eur J Pediatr. 2015;174(11):1503–9. https://doi.org/10.1007/s00431-015-2561-1.

    Article  CAS  PubMed  Google Scholar 

  77. Pandey A, Gangopadhyay AN, Sharma SP, Kumar V, Gupta DK, Gopal SC. Evaluation of topical steroids in the treatment of superficial hemangioma. Skinmed. 2010;8(1):9–11.

    PubMed  Google Scholar 

  78. Pandey V, Tiwari P, Sharma SP, Kumar R, Singh OP. Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol. Int J Oral Maxillofac Surg. 2018;47(7):908–12. https://doi.org/10.1016/j.ijom.2018.03.024.

    Article  CAS  PubMed  Google Scholar 

  79. Kaylani S, Theos AJ, Pressey JG. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatr Dermatol. 2013;30(6):e194–7. https://doi.org/10.1111/pde.12023.

    Article  PubMed  Google Scholar 

  80. Perez J, Pardo J, Gomez C. Vincristine—an effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol. 2002;41(2):197–9. https://doi.org/10.1080/028418602753669607.

    Article  PubMed  Google Scholar 

  81. Enjolras O, Brevière GM, Roger G, Tovi M, Pellegrino B, Varotti E, et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr. 2004;11(2):99–107. https://doi.org/10.1016/j.arcped.2003.10.014.

    Article  CAS  PubMed  Google Scholar 

  82. Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol. 2010;146(5):564–5. https://doi.org/10.1001/archdermatol.2010.67.

    Article  PubMed  Google Scholar 

  83. Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics. 2013;131(6):e1739–47. https://doi.org/10.1542/peds.2012-3828.

    Article  PubMed  Google Scholar 

  84. Chakkittakandiyil A, Phillips R, Frieden IJ, Siegfried E, Lara-Corrales I, Lam J, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol. 2012;29(1):28–31. https://doi.org/10.1111/j.1525-1470.2011.01664.x.

    Article  PubMed  Google Scholar 

  85. Khan M, Boyce A, Prieto-Merino D, Svensson Å, Wedgeworth E, Flohr C. The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis. Acta Derm Venereol. 2017;97(10):1167–71. https://doi.org/10.2340/00015555-2681.

    Article  CAS  PubMed  Google Scholar 

  86. Hu L, Huang HZ, Li X, Lin XX, Li W. Open-label nonrandomized left-right comparison of imiquimod 5% ointment and timolol maleate 0.5% eye drops in the treatment of proliferating superficial infantile hemangioma. Dermatology. 2015;230(2):150–5. https://doi.org/10.1159/000369164.

    Article  CAS  PubMed  Google Scholar 

  87. Weibel L, Barysch MJ, Scheer HS, Königs I, Neuhaus K, Schiestl C, et al. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. Pediatr Dermatol. 2016;33(2):184–90. https://doi.org/10.1111/pde.12767.

    Article  PubMed  Google Scholar 

  88. Zheng L, Li Y. Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. Arch Dermatol Res. 2018;310(4):261–9. https://doi.org/10.1007/s00403-018-1815-y.

    Article  PubMed  Google Scholar 

  89. Muñoz-Garza FZ, Ríos M, Roé-Crespo E, Bernabeu-Wittel J, Montserrat-García MT, Puig L, et al. Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage: a randomized clinical trial. JAMA Dermatol. 2021. https://doi.org/10.1001/jamadermatol.2021.0596.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Borok J, Gangar P, Admani S, Proudfoot J, Friedlander SF. Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial. Br J Dermatol. 2018;178(1):e51–2. https://doi.org/10.1111/bjd.15865.

    Article  CAS  PubMed  Google Scholar 

  91. Drolet BA, Boakye-Agyeman F, Harper B, Holland K, Lewandowski A, Stefanko N, et al. Systemic timolol exposure following topical application to infantile hemangiomas. J Am Acad Dermatol. 2020;82(3):733–6. https://doi.org/10.1016/j.jaad.2019.02.029.

    Article  PubMed  Google Scholar 

  92. Püttgen K, Lucky A, Adams D, Pope E, McCuaig C, Powell J, et al. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2016. https://doi.org/10.1542/peds.2016-0355.

    Article  PubMed  Google Scholar 

  93. Shedden AH, Laurence J, Barrish A, Olah TV. Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc Ophthalmol. 2001;103(1):73–9. https://doi.org/10.1023/a:1017962731813.

    Article  CAS  PubMed  Google Scholar 

  94. Hoeger PH, Harper JI, Baselga E, Bonnet D, Boon LM, Atti MCD, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855–65. https://doi.org/10.1007/s00431-015-2570-0.

    Article  CAS  PubMed  Google Scholar 

  95. Dalla Costa R, Prindaville B, Wiss K. Doing the math: a simple approach to topical timolol dosing for infantile hemangiomas. Pediatr Dermatol. 2018;35(2):276–7. https://doi.org/10.1111/pde.13407.

    Article  PubMed  Google Scholar 

  96. Mannschreck DB, Huang AH, Lie E, Psoter K, Puttgen K. Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2019;36(3):283–9. https://doi.org/10.1111/pde.13816.

    Article  PubMed  Google Scholar 

  97. Qiao J, Lin J, Zhang D, Li J, Chen C, Yu H, et al. Efficacy of combined topical timolol and oral propranolol for treating infantile hemangioma: a meta-analysis of randomized controlled trials. Front Pharmacol. 2020;11: 554847. https://doi.org/10.3389/fphar.2020.554847.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. McCuaig CC, Dubois J, Powell J, Belleville C, David M, Rousseau E, et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol. 2009;26(2):203–12. https://doi.org/10.1111/j.1525-1470.2008.00857.x.

    Article  PubMed  Google Scholar 

  99. Thayal PK, Bhandari PS, Sarin YK. Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas. Plast Reconstr Surg. 2012;129(4):733e-e735. https://doi.org/10.1097/PRS.0b013e318245e739.

    Article  CAS  PubMed  Google Scholar 

  100. Kinzinger MR, Strong EB, Bernard J, Steele TO. Intralesional bevacizumab for the treatment of recurrent sinonasal hemangioma. Ann Otol Rhinol Laryngol. 2018;127(12):969–73. https://doi.org/10.1177/0003489418802288.

    Article  PubMed  Google Scholar 

  101. Sabry HH, Sorour NE, Akl EM. Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma. J Dermatol Treat. 2020;31(3):279–84. https://doi.org/10.1080/09546634.2019.1590521.

    Article  CAS  Google Scholar 

  102. Chinnadurai S, Sathe NA, Surawicz T. Laser treatment of infantile hemangioma: a systematic review. Lasers Surg Med. 2016;48(3):221–33. https://doi.org/10.1002/lsm.22455.

    Article  PubMed  Google Scholar 

  103. Chelleri C, Monzani NA, Gelmetti C, Milani GP, Fossali EF, Galeone C, et al. Residual lesions after pharmacological and dye-laser treatment of infantile hemangiomas: critical review of 432 cases. Lasers Surg Med. 2020;52(7):597–603. https://doi.org/10.1002/lsm.23205.

    Article  PubMed  Google Scholar 

  104. Wang JY, Ighani A, Ayala AP, Akita S, Lara-Corrales I, Alavi A. Medical, surgical, and wound care management of ulcerated infantile hemangiomas: a systematic review [formula: see text]. J Cutan Med Surg. 2018;22(5):495–504. https://doi.org/10.1177/1203475418770570.

    Article  PubMed  Google Scholar 

  105. Metry D, Frieden IJ, Hess C, Siegel D, Maheshwari M, Baselga E, et al. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol. 2013;30(1):71–89. https://doi.org/10.1111/j.1525-1470.2012.01879.x.

    Article  PubMed  Google Scholar 

  106. McCuaig CC, Cohen L, Powell J, Hatami A, Marcoux D, Maari C, et al. Therapy of ulcerated hemangiomas. J Cutan Med Surg. 2013;17(4):233–42. https://doi.org/10.2310/7750.2012.12037.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Dermatology, Department of Pediatrics, Sainte-Justine University Hospital Center, University of Montreal, Montreal, QC, Canada

    Caroline Colmant & Julie Powell

Authors
  1. Caroline Colmant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julie Powell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline Colmant.

Ethics declarations

Funding

Not applicable.

Conflicts of interest

Julie Powell: Advisory board and speaker: Pierre-Fabre Dermatology, Pfizer, Sanofi-Genzyme, Novartis. Caroline Colmant: no conflicts to declare.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent to publish

Consent to publish identifying photos was obtained from the patients/parents.

Author contributions

Both authors contributed to the writing and revision of this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Colmant, C., Powell, J. Medical Management of Infantile Hemangiomas: An Update. Pediatr Drugs 24, 29–43 (2022). https://doi.org/10.1007/s40272-021-00477-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-021-00477-9

Search

Navigation